Tietjen_2012_PLoS.One_7_e37437

Reference

Title : Segregation of LIPG, CETP, and GALNT2 mutations in Caucasian families with extremely high HDL cholesterol - Tietjen_2012_PLoS.One_7_e37437
Author(s) : Tietjen I , Hovingh GK , Singaraja RR , Radomski C , Barhdadi A , McEwen J , Chan E , Mattice M , Legendre A , Franchini PL , Dube MP , Kastelein JJ , Hayden MR
Ref : PLoS ONE , 7 :e37437 , 2012
Abstract :

To date, few mutations are described to underlie highly-elevated HDLc levels in families. Here we sequenced the coding regions and adjacent sequence of the LIPG, CETP, and GALNT2 genes in 171 unrelated Dutch Caucasian probands with HDLc>/=90th percentile and analyzed segregation of mutations with lipid phenotypes in family members. In these probands, mutations were most frequent in LIPG (12.9%) followed by GALNT2 (2.3%) and CETP (0.6%). A total of 6 of 10 mutations in these three genes were novel (60.0%), and mutations segregated with elevated HDLc in families. Interestingly, the LIPG mutations N396S and R476W, which usually result in elevated HDLc, were unexpectedly found in 6 probands with low HDLc (i.e., <=10th percentile). However, 5 of these probands also carried mutations in ABCA1, LCAT, or LPL. Finally, no CETP and GALNT2 mutations were found in 136 unrelated probands with low HDLc. Taken together, we show that rare coding and splicing mutations in LIPG, CETP, and GALNT2 are enriched in persons with hyperalphalipoproteinemia and segregate with elevated HDLc in families. Moreover, LIPG mutations do not overcome low HDLc in individuals with ABCA1 and possibly LCAT and LPL mutations, indicating that LIPG affects HDLc levels downstream of these proteins.

PubMedSearch : Tietjen_2012_PLoS.One_7_e37437
PubMedID: 22952570

Related information

Citations formats

Tietjen I, Hovingh GK, Singaraja RR, Radomski C, Barhdadi A, McEwen J, Chan E, Mattice M, Legendre A, Franchini PL, Dube MP, Kastelein JJ, Hayden MR (2012)
Segregation of LIPG, CETP, and GALNT2 mutations in Caucasian families with extremely high HDL cholesterol
PLoS ONE 7 :e37437

Tietjen I, Hovingh GK, Singaraja RR, Radomski C, Barhdadi A, McEwen J, Chan E, Mattice M, Legendre A, Franchini PL, Dube MP, Kastelein JJ, Hayden MR (2012)
PLoS ONE 7 :e37437